Li-Fraumeni SyndromeNCT01443468
Clinical and Genetic Studies of Li-Fraumeni Syndrome
An observational study of Li-Fraumeni Syndrome and Neoplasms, run by National Cancer Institute (NCI) at 2 sites in United States.
Trial summary
Background: Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
- How many people
- 5,000 participants
- Where
- 2 sitesUnited States
- Study dates
- 17 Jan 2012to not given
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Eligibility for the LFS study population: - A family or personal medical history of cancers consistent with the diagnosis of LFS or LFL; or, - A personal history of a germline TP53 mutation; or, - A first- or second- degree relative of a TP53 mutation carrier, regardless of mutation status; or, - A personal history of three or more LFS-related primary cancers; or, - A personal history of adrenal cortical carcinoma or choroid plexus carcinoma at any age
Who may be able to join
- On referral, persons of all ages will be considered for inclusion in the study
- because of either:
- A family or personal medical history of neoplasia consistent with the diagnosis of LFS or LFL; or,
- A personal history of a germline TP53 mutation; or,
- A first- or second- degree relative of a TP53 mutation carrier, regardless of mutation status; or,
- A personal history of three or more LFS-related primary cancers; or,
Show all 31Show fewer
- A personal history of adrenal cortical carcinoma or choroid plexus carcinoma at any age, regardless of family history
- Personal and family medical history must be verified through questionnaires, interviews, review
- of medical records and/or review of pathology slides.
- There are 72 families who have previously enrolled in the pilot study under protocol 78-C-0039.
- As the eligibility criteria remain the same, these families will be eligible for this protocol and will be invited to sign the new consent.
- -Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
- For both the Field and Clinical Center Cohort, the PI will ensure that study investigators will
- identify an appropriate LAR consistent with requirements of Policy 403 and will obtain consent
- from the LAR as outlined in the consent process before initiating research interventions.
- -Pregnant women
- In order to study the lifetime rates of cancer development in all individuals with Li-Fraumeni
- syndrome, we will need to evaluate what effect pregnancy may have on rate of cancer
- development both in affected individuals and unaffected family controls. Additionally, some
- cancers are known to have an increased risk of development in the context of pregnancy and
- lactation. Exclusion of pregnant women would preclude understanding of these cancer risks for
- an important subset of the population.
- Pregnant women are eligible for enrollment on the data collection component of this study.
- Pregnant women will be included in this study as several endpoints may be assessed during
- pregnancy; counseling, education, and other minimal risk procedures (i.e. blood draw) may be
- done. We will postpone full clinical evaluations at the Clinical Center of pregnant women until
- the subject has recovered post-partum.
- All screening studies, for women who are pregnant, or breastfeeding will be deferred while the
- woman is pregnant or breastfeeding. Pregnancy testing will be performed for females of childbearing age prior to imaging studies, and the test results must be negative prior to the scan..
- The risk to the fetus and pregnant woman would be no greater than minimal for procedures that
- are performed.
Who cannot join
- Referred individuals and families whose reported diagnoses cannot be verified
- Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would preclude the ability to participate in clinical research
- Women who are pregnant will not be eligible for the cancer screening protocol until they recover post-partum. Women participating in the cancer screening protocol will discontinue this component if they become pregnant while on study. Once they recover post-partum, they can continue the cancer screening protocol.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
National Cancer Institute - Shady Grove
Bethesda, Maryland, 20892
Payal Khincha, M.D., 240-276-7267, payal.khincha@nih.gov
- Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
For more information at the NIH Clinical Center contact National Cancer Institute Referral Office, 888-624-1937
About this study
Official title: Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Background:
- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may increase or decrease cancer risk in people with the syndrome.
Read more
Objectives:
- To learn more about the types of cancers that occur in individuals with LFS.
- To study the role of the TP53 gene in the development of cancer.
- To look for other possible genes that cause LFS
- To study the effect of LFS diagnosis on families.
- To determine if environmental factors or other genes can change a person s cancer risk associated with LFS.
Eligibility:
- Individuals with a family or personal medical history of cancers consistent with LFS.
- Individuals with a family or personal medical history of cancers that does not meet the diagnosis of LFS, but the history is suggestive for LFS (meets the diagnosis for the so-called Li-Fraumeni like syndrome)
- Individuals with certain rare cancers
- Individuals with a family or personal history of a TP53 gene mutation, with or without related cancer(s).
Design:
- Participants will fill out a medical history questionnaire and a family history questionnaire.
- Blood samples will be collected for DNA and for storage. Cheek cell samples may be collected if blood cannot be obtained for DNA. Participants can choose to have or not have cancer screening with blood tests, imaging studies, and other exams.
- Participants will complete questionnaires about their worries about cancer, stress levels, and coping strategies. Diet and physical activity questionnaires will also be given. Other psychological tests may be given as needed.
- Participants will be monitored for several years, with regular followup visits to the National Institutes of Health, if indicated. Any changes in health or cancer status will be recorded.
Read the detailed description
Study Description:
This is a natural history study involving questionnaires, clinical and research evaluations, clinical and research laboratory tests, review of
medical records, and cancer surveillance. This is a prospective long-term study of individuals at high risk of cancer due to Li-Fraumeni Syndrome (LFS) or Li-Fraumeni-Like Syndrome (LFL), using a cohort approach. Enrollees are invited to participate in all aspects of the study but can choose to opt out of specific part(s).
Objectives:
Primary Objectives:
- To ascertain/enroll individuals and families with Li-Fraumeni Syndrome (LFS) and Li-Fraumeni-Like Syndrome (LFL)
- To evaluation and define the clinical spectrum and natural history of disease in LFS and LFL
- To quantify cumulative cancer risk in individuals with LFS or LFL
- To develop a cancer screening program for individuals with LFS or LFL
- To investigate the mechanisms of tumorigenesis in LFS-related tumors (e.g., cell proliferation, growth regulation, apoptosis)
- To identify genetic determinants, environmental factors, and gene-environment interactions that potentially modify cancer risk in these high-risk individuals
- To evaluate the psychological, behavioral, and social functioning effects of LFS on affected individuals and their family members
- To explore the plausibility of lifestyle interventions as potential strategies for cancer risk reduction
- To create an annotated biospecimen repository of LFS-related for translational, etiologic, and outcomes research
Secondary Objectives:
-To evaluate specific tumor characteristics, including histologies (e.g., leukemia types, brain tumor types, etc.) of cancers
diagnosed in individuals with LFS or LFL.
-To evaluate the potential effect of therapeutic radiation and radiation exposure from diagnostic/screening imaging studies on
cancer risk.
- To provide education, cancer risk assessment, and risk management recommendations for study participants.
- To collect clinical data related to the treatment of LFS-related cancers, so that outcome and survival may be evaluated.
Endpoints: Primary Endpoint:
-Occurrence of cancer in individuals and families with LFS or LFL
- Conditions
- Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
- Keywords
- Tp53, Cancer, Hereditary, Genetic Testing, Screening
- Medical subject headings
- Li-Fraumeni Syndrome, Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Patients within a family with a known TP53 mutation who are positive for that mutation. | |
| 2 | Patients within a family with a known TP53 mutation who are negative for that mutation. | |
| 3 | Unaffected family members. | |
| 4 | Patients who meet clinical LFS criteria but haven't had TP53 testing. | |
| 5 | Patients within a family with an negative/unknown TP53 mutation. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence
Learn more about the types of cancers that occur in individuals with LFS and the age at which these cancers are usually found
Measured: ongoing
Multiple measures
Explore ways to lower cancer risk
Measured: ongoing
Multiple measures
Explore the typical features of the cancers diagnosed in individuals with LFS
Measured: ongoing
Multiple measures
Explore the psychological and social functioning issues faced by LFS families
Measured: ongoing
Multiple measures
Explore the best ways to look for cancers early in individuals with LFS
Measured: ongoing
Multiple measures
Determine if there is any connection between specific mutations in the TP53 gene and the risk of certain type of cancers
Measured: ongoing
Multiple measures
Determine if there are any environmental factors or other genes that can change a person's cancer risk associated with LFS
Measured: ongoing
Multiple measures
Determine how often a change (mutation) in the TP53 gene is found in families in which LFS is suspected
Measured: ongoing
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2011 (estimated)
- Study start17 Jan 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Li-Fraumeni SyndromeStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Family based
- Time perspective
- Prospective
- Enrolment
- 5,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Payal P Khincha, M.D., Principal investigator, National Cancer Institute (NCI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01443468
- Sponsor's protocol ID
- 110255
- Other IDs
- 11-C-0255
- Status last verified
- 16 Oct 2026
- First submitted
- 28 Sep 2011
- Last updated
- 5 Nov 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U, Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF Jr, Savage SA. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012 Oct;205(10):479-87. doi: 10.1016/j.cancergen.2012.06.008. Epub 2012 Aug 29.
PubMed 22939227Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011 Jun;12(6):559-67. doi: 10.1016/S1470-2045(11)70119-X. Epub 2011 May 19.
PubMed 21601526Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011 Apr;2(4):475-84. doi: 10.1177/1947601911413466.
PubMed 21779515Rising CJ, Huelsnitz CO, Shepherd RF, Klein WMP, Sleight AG, Wilsnack C, Boyd P, Feldman AE, Khincha PP, Werner-Lin A. Diet and physical activity behaviors: how are they related to illness perceptions, coping, and health-related quality of life in young people with hereditary cancer syndromes? J Behav Med. 2024 Aug;47(4):707-720. doi: 10.1007/s10865-024-00489-z. Epub 2024 Apr 20.
PubMed 38642305Rising CJ, Wilsnack C, Boyd P, Sleight AG, Hutson SP, Khincha PP, Werner-Lin A. Family communication challenges of adolescents and young adults with Li-Fraumeni syndrome: Implications for psychosocial care. Patient Educ Couns. 2022 Nov;105(11):3259-3266. doi: 10.1016/j.pec.2022.07.012. Epub 2022 Jul 20.
PubMed 35918231Werner-Lin A, Forbes Shepherd R, Young JL, Wilsnack C, Merrill SL, Greene MH, Khincha PP. Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body. Soc Sci Med. 2022 May;301:114905. doi: 10.1016/j.socscimed.2022.114905. Epub 2022 Mar 17.
PubMed 35367908de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL, Best AF, Savage SA. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021 Dec;22(12):1787-1798. doi: 10.1016/S1470-2045(21)00580-5. Epub 2021 Nov 12.
PubMed 34780712
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
- ClinicalTrials.gov ID
- NCT01443468
- Acronym / sponsor ID
- 110255
- Conditions
- Li-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
- Keywords
- Tp53, Cancer, Hereditary, Genetic Testing, Screening
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 5,000 participants (estimated)
- Lead sponsor
- National Cancer Institute (NCI)US National Institutes of Health
- Study start
- 17 Jan 2012 (actual)
- First posted
- 29 Sep 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may increase or decrease cancer risk in people with the syndrome.
Objectives:
- To learn more about the types of cancers that occur in individuals with LFS.
- To study the role of the TP53 gene in the development of cancer.
- To look for other possible genes that cause LFS
- To study the effect of LFS diagnosis on families.
- To determine if environmental factors or other genes can change a person s cancer risk associated with LFS.
Eligibility:
- Individuals with a family or personal medical history of cancers consistent with LFS.
- Individuals with a family or personal medical history of cancers that does not meet the diagnosis of LFS, but the history is suggestive for LFS (meets the diagnosis for the so-called Li-Fraumeni like syndrome)
- Individuals with certain rare cancers
- Individuals with a family or personal history of a TP53 gene mutation, with or without related cancer(s).
Design:
- Participants will fill out a medical history questionnaire and a family history questionnaire.
- Blood samples will be collected for DNA and for storage. Cheek cell samples may be collected if blood cannot be obtained for DNA. Participants can choose to have or not have cancer screening with blood tests, imaging studies, and other exams.
- Participants will complete questionnaires about their worries about cancer, stress levels, and coping strategies. Diet and physical activity questionnaires will also be given. Other psychological tests may be given as needed.
- Participants will be monitored for several years, with regular followup visits to the National Institutes of Health, if indicated. Any changes in health or cancer status will be recorded.
Detailed description
Study Description:
This is a natural history study involving questionnaires, clinical and research evaluations, clinical and research laboratory tests, review of
medical records, and cancer surveillance. This is a prospective long-term study of individuals at high risk of cancer due to Li-Fraumeni Syndrome (LFS) or Li-Fraumeni-Like Syndrome (LFL), using a cohort approach. Enrollees are invited to participate in all aspects of the study but can choose to opt out of specific part(s).
Objectives:
Primary Objectives:
- To ascertain/enroll individuals and families with Li-Fraumeni Syndrome (LFS) and Li-Fraumeni-Like Syndrome (LFL)
- To evaluation and define the clinical spectrum and natural history of disease in LFS and LFL
- To quantify cumulative cancer risk in individuals with LFS or LFL
- To develop a cancer screening program for individuals with LFS or LFL
- To investigate the mechanisms of tumorigenesis in LFS-related tumors (e.g., cell proliferation, growth regulation, apoptosis)
- To identify genetic determinants, environmental factors, and gene-environment interactions that potentially modify cancer risk in these high-risk individuals
- To evaluate the psychological, behavioral, and social functioning effects of LFS on affected individuals and their family members
- To explore the plausibility of lifestyle interventions as potential strategies for cancer risk reduction
- To create an annotated biospecimen repository of LFS-related for translational, etiologic, and outcomes research
Secondary Objectives:
-To evaluate specific tumor characteristics, including histologies (e.g., leukemia types, brain tumor types, etc.) of cancers
diagnosed in individuals with LFS or LFL.
-To evaluate the potential effect of therapeutic radiation and radiation exposure from diagnostic/screening imaging studies on
cancer risk.
- To provide education, cancer risk assessment, and risk management recommendations for study participants.
- To collect clinical data related to the treatment of LFS-related cancers, so that outcome and survival may be evaluated.
Endpoints: Primary Endpoint:
-Occurrence of cancer in individuals and families with LFS or LFL
Study design
- Observational model
- Family based
- Time perspective
- Prospective
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| 1 | – | –Patients within a family with a known TP53 mutation who are positive for that mutation. |
| 2 | – | –Patients within a family with a known TP53 mutation who are negative for that mutation. |
| 3 | – | –Unaffected family members. |
| 4 | – | –Patients who meet clinical LFS criteria but haven't had TP53 testing. |
| 5 | – | –Patients within a family with an negative/unknown TP53 mutation. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Eligibility for the LFS study population: - A family or personal medical history of cancers consistent with the diagnosis of LFS or LFL; or, - A personal history of a germline TP53 mutation; or, - A first- or second- degree relative of a TP53 mutation carrier, regardless of mutation status; or, - A personal history of three or more LFS-related primary cancers; or, - A personal history of adrenal cortical carcinoma or choroid plexus carcinoma at any age
Key inclusion criteria (31 listed)
- On referral, persons of all ages will be considered for inclusion in the study
- A family or personal medical history of neoplasia consistent with the diagnosis of LFS or LFL; or,
- A personal history of a germline TP53 mutation; or,
- A first- or second- degree relative of a TP53 mutation carrier, regardless of mutation status; or,
- A personal history of three or more LFS-related primary cancers; or,
Key exclusion criteria (3 listed)
- Referred individuals and families whose reported diagnoses cannot be verified
- Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would preclude the ability to participate in clinical research
- Women who are pregnant will not be eligible for the cancer screening protocol until they recover post-partum. Women participating in the cancer screening protocol will discontinue this component if they become pregnant while on study. Once they recover post-partum, they can continue the cancer screening protocol.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence
Time frame: ongoing
Learn more about the types of cancers that occur in individuals with LFS and the age at which these cancers are usually found
Multiple measures
Time frame: ongoing
Explore ways to lower cancer risk
Multiple measures
Time frame: ongoing
Explore the typical features of the cancers diagnosed in individuals with LFS
Multiple measures
Time frame: ongoing
Explore the psychological and social functioning issues faced by LFS families
Multiple measures
Time frame: ongoing
Explore the best ways to look for cancers early in individuals with LFS
Multiple measures
Time frame: ongoing
Determine if there is any connection between specific mutations in the TP53 gene and the risk of certain type of cancers
Multiple measures
Time frame: ongoing
Determine if there are any environmental factors or other genes that can change a person's cancer risk associated with LFS
Multiple measures
Time frame: ongoing
Determine how often a change (mutation) in the TP53 gene is found in families in which LFS is suspected
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Background: PubMed 22939227Mai PL, Malkin D, Garber JE, Schiffman JD, Weitzel JN, Strong LC, Wyss O, Locke L, Means V, Achatz MI, Hainaut P, Frebourg T, Evans DG, Bleiker E, Patenaude A, Schneider K, Wilfond B, Peters JA, Hwang PM, Ford J, Tabori U, Ognjanovic S, Dennis PA, Wentzensen IM, Greene MH, Fraumeni JF Jr, Savage SA. Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genet. 2012 Oct;205(10):479-87. doi: 10.1016/j.cancergen.2012.06.008. Epub 2012 Aug 29.
- Background: PubMed 21601526Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011 Jun;12(6):559-67. doi: 10.1016/S1470-2045(11)70119-X. Epub 2011 May 19.
- Background: PubMed 21779515Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011 Apr;2(4):475-84. doi: 10.1177/1947601911413466.
- Derived from this study: PubMed 38642305Rising CJ, Huelsnitz CO, Shepherd RF, Klein WMP, Sleight AG, Wilsnack C, Boyd P, Feldman AE, Khincha PP, Werner-Lin A. Diet and physical activity behaviors: how are they related to illness perceptions, coping, and health-related quality of life in young people with hereditary cancer syndromes? J Behav Med. 2024 Aug;47(4):707-720. doi: 10.1007/s10865-024-00489-z. Epub 2024 Apr 20.
- Derived from this study: PubMed 35918231Rising CJ, Wilsnack C, Boyd P, Sleight AG, Hutson SP, Khincha PP, Werner-Lin A. Family communication challenges of adolescents and young adults with Li-Fraumeni syndrome: Implications for psychosocial care. Patient Educ Couns. 2022 Nov;105(11):3259-3266. doi: 10.1016/j.pec.2022.07.012. Epub 2022 Jul 20.
- Derived from this study: PubMed 35367908Werner-Lin A, Forbes Shepherd R, Young JL, Wilsnack C, Merrill SL, Greene MH, Khincha PP. Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body. Soc Sci Med. 2022 May;301:114905. doi: 10.1016/j.socscimed.2022.114905. Epub 2022 Mar 17.
- Derived from this study: PubMed 34780712de Andrade KC, Khincha PP, Hatton JN, Frone MN, Wegman-Ostrosky T, Mai PL, Best AF, Savage SA. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021 Dec;22(12):1787-1798. doi: 10.1016/S1470-2045(21)00580-5. Epub 2021 Nov 12.
- NIH Clinical Center Detailed Web PageLink provided by the sponsor.
Related trials for Li-Fraumeni Syndrome
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
Not yet recruiting
Reduce All Avoidable Cancer-promoting Exposures in Individuals at High Genetic Risk of Cancer Carrying a Constitutional Variant of the TP53 Gene
Adult Carriers of a Pathogenic or Probably Pathogenic (Class 4 and 5) Germline Variation in the TP53 Gene
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
RecruitingObservational study
CfDNA in Hereditary And High-risk Malignancies 2
Hereditary Cancer Syndrome
RecruitingObservational study
Willingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling
Li-Fraumeni Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Payal P Khincha, M.D. principal investigator
National Cancer Institute (NCI)
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Li-Fraumeni Syndrome and Neoplasms, run by National Cancer Institute (NCI) at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 31 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact NCI Family Study Referrals ((800) 518-8474, ncifamilystudyreferrals@mail.nih.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence (time frame: ongoing). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01443468, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.